ASTRAZENECA SECURES NHS ACCESS TO IMFINZI▼(DURVALUMAB) IN COMBINATION WITH GEMCITABINE AND CISPLATIN IN ADVANCED BILIARY TRACT CANCER ACROSS ENGLAND A

Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) has been recommended by the National Institute for Health and Care Excellence (NICE) for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1Durvalumab is AstraZeneca UK&rsq...

Related Keywords

Manchester ,United Kingdom ,London ,City Of ,Great Britain ,Helen Morement ,Ptom Keith Roach ,David Brocklehurst ,Cholangiocarcinoma Charity ,Senior Lecturer University Of Manchester ,National Institute For Health ,Astrazeneca ,National Institute ,Care Excellence ,Astrazeneca United Kingdom ,Senior Lecturer ,Honorary Consultant ,Innovation Passport ,Innovative Licensing ,Access Pathway ,